Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Coformulated favezelimab/pembrolizumab clinical trials

Also listed in trial records as MK-4280A, Coformulation favezelimab/pembrolizumab
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 3 trials in our USA, Spain, Italy, Canada, South Korea, Australia, Israel, UK, France, Netherlands, Poland, Switzerland, Austria, Taiwan, Ireland, China, Germany, Belgium, Sweden, Denmark, Czechia, Norway, Portugal, Turkey, Brazil, Mexico, Japan and Singapore registers that name Coformulated favezelimab/pembrolizumab as an intervention. Synced 17 Nov 2026
3Current trials
1Recruiting now
1Lead sponsor
28Country registers
At a glance

Coformulated favezelimab/pembrolizumab is named as an intervention in 3 current clinical trials in our USA, Spain, Italy, Canada, South Korea, Australia, Israel, UK, France, Netherlands, Poland, Switzerland, Austria, Taiwan, Ireland, China, Germany, Belgium, Sweden, Denmark, Czechia, Norway, Portugal, Turkey, Brazil, Mexico, Japan and Singapore registers. 1 is recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is Merck Sharp & Dohme LLC. The most-studied condition is Solid Tumors.

Patient leaflets for Coformulated favezelimab/pembrolizumab

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting133%
  • Active, closed267%

Trials by phase

  • Phase 1/2267%
  • Phase 3133%
01

Clinical trials of Coformulated favezelimab/pembrolizumab

3 trials
StudyPhaseStatusLead sponsorRegisters
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873 · Solid Tumors, Hematologic Malignancies
Phase 3 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
NCT04938817 · Small Cell Lung Carcinoma
Phase 1/2 Active, closed Merck Sharp & Dohme LLC USA, Spain, Italy, Poland, Switzerland, Austria, Canada, South Korea, Australia, Israel
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
NCT05845814 · Metastatic Urothelial Carcinoma, Urothelial Neoplasms
Phase 1/2 Active, closed Merck Sharp & Dohme LLC UK, USA, France, Spain, Italy, Netherlands, Canada, South Korea, Taiwan, Australia, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Coformulated favezelimab/pembrolizumab

5 conditions
Solid Tumors1Hematologic Malignancies1Metastatic Urothelial Carcinoma1Urothelial Neoplasms1Small Cell Lung Carcinoma1
05

Related compounds

06

Questions about Coformulated favezelimab/pembrolizumab trials

How many clinical trials are testing Coformulated favezelimab/pembrolizumab?

3 current trials in our USA, Spain, Italy, Canada, South Korea, Australia, Israel, UK, France, Netherlands, Poland, Switzerland, Austria, Taiwan, Ireland, China, Germany, Belgium, Sweden, Denmark, Czechia, Norway, Portugal, Turkey, Brazil, Mexico, Japan and Singapore registers name Coformulated favezelimab/pembrolizumab (also registered as MK-4280A) as a drug or biological intervention, as of the registry sync on 17 November 2026. Completed and withdrawn studies are not counted.

Are Coformulated favezelimab/pembrolizumab trials recruiting patients?

Yes. 1 of the 3 trials is recruiting: 1 with sites in USA, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Canada, 1 with sites in South Korea, 1 with sites in Australia, 1 with sites in Israel, 1 with sites in UK, 1 with sites in France, 1 with sites in Netherlands, 1 with sites in Poland, 1 with sites in Switzerland, 1 with sites in Austria, 1 with sites in Taiwan, 1 with sites in Ireland, 1 with sites in China, 1 with sites in Germany, 1 with sites in Belgium, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Czechia, 1 with sites in Norway, 1 with sites in Portugal, 1 with sites in Turkey, 1 with sites in Brazil, 1 with sites in Mexico, 1 with sites in Japan and 1 with sites in Singapore. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Coformulated favezelimab/pembrolizumab clinical trials?

The lead sponsor is Merck Sharp & Dohme LLC. The number in brackets is how many trials each organisation leads.

Are there Coformulated favezelimab/pembrolizumab clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Coformulated favezelimab/pembrolizumab works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Coformulated favezelimab/pembrolizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Coformulated favezelimab/pembrolizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 17 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.